Search - tctmd.com

Displaying 1 - 20 of 216

Sort: Relevancy | Date

News Conference News ACC 2025

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

L.A. McKeown

April 10, 2025

News Conference News ACC 2025

RACER: No Change in Cardiac Arrests During Marathons, but Survival Is Up

Michael O'Riordan

April 08, 2025

News Conference News ACC 2025

Nurses Can Be Pivotal in Post-ACS Secondary Prevention: ALLEPRE

Caitlin E. Cox

April 02, 2025

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

News Conference News ACC 2025

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

L.A. McKeown

March 30, 2025

News Conference News ACC 2025

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

Michael O'Riordan

March 30, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

News Daily News ACC 2025

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

L.A. McKeown

March 29, 2025

News Conference News ACC 2025

WARRIOR: No Clear Answers on How to Best Treat INOCA

Yael L. Maxwell

March 29, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Conference News ACC 2024

NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

Yael L. Maxwell

July 03, 2024

News Conference News ACC 2024

HUDDLE Up! High BP and Cardiac Changes Prevalent in Retired NFL Players

Michael O'Riordan

April 15, 2024

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

News Conference News ACC 2024

Telemedicine Strategy After MI Scores a Win in TELE-ACS

Caitlin E. Cox

April 12, 2024

News Conference News ACC 2024

KARDIA-2: Zilebesiran Drops BP on Top of Common Antihypertensives

Shelley Wood

April 11, 2024

News Conference News ACC 2024

BE ACTIVE: Gaming for Points and Money Can Boost Step Counts

L.A. McKeown

April 11, 2024

News Conference News ACC 2024

Need a Statin for Primary Prevention? There’s an App for That

Michael O'Riordan

April 10, 2024

News Conference News ACC 2024

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Yael L. Maxwell

April 09, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

Another Win for TAVI in Low-to-Intermediate Risk Patients

News Conference News ACC 2024

Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6

Yael L. Maxwell

April 08, 2024

Advertisement

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

RACER: No Change in Cardiac Arrests During Marathons, but Survival Is Up

Nurses Can Be Pivotal in Post-ACS Secondary Prevention: ALLEPRE

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

WARRIOR: No Clear Answers on How to Best Treat INOCA

What’s Going to Be Hot at ACC 2025?

NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

HUDDLE Up! High BP and Cardiac Changes Prevalent in Retired NFL Players

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Telemedicine Strategy After MI Scores a Win in TELE-ACS

KARDIA-2: Zilebesiran Drops BP on Top of Common Antihypertensives

BE ACTIVE: Gaming for Points and Money Can Boost Step Counts

Need a Statin for Primary Prevention? There’s an App for That

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content